Chronic Hepatitis B(CHB) is a serious sequel after Hepatitis B Virus infection, although the rate of chronicity is inverse with age but it may be associated with a significant proportion of deaths related to cirrhosis and liver cancer. HBV serology and measurement of hepatocytic enzymes with viral load can predict disease prognosis and response to treatment. HBeAg refers to a high viral replication and associated with more infectivity to others. This study aimed to determine the impact of HBeAg status in chronically infected patients on various baseline tests. A total of 90 patients with CHB infection who were included in this study. Several standardized measures used for liver function tests, viral load and hepatitis B serological markers. HBeAg was negative in 81/90 (90%) patients and positive in 9/90(10%). There was significant association between HBeAg serostatus and HBV-DNA viral load (p=0.042), as more than half of the cases (55.6%) had high levels of HBV serum DNA (=2000 IU/ml) and positive HBeAg compared to 24.7% of cases with negative HBeAg. HBeAg seroconversion was not associated with liver function tests, modes of transmission, duration of chronicity, marital status, gender and age. We concluded that HBeAg sero-negativity among the studied cases can predict the inactive or reactive phase of chronic hepatitis B, if the latter is associated with high viral loads, so that further studies are needed to find out associated precore mutants.
Cite this article:
Aya Raed Alheany, Shatha Farouk Abdullah. Status of HBeAg in association with other baseline tests in Iraqi patients with CHB. Research Journal of Pharmacy and Technology. 2022; 15(8):3475-8. doi: 10.52711/0974-360X.2022.00582
Aya Raed Alheany, Shatha Farouk Abdullah. Status of HBeAg in association with other baseline tests in Iraqi patients with CHB. Research Journal of Pharmacy and Technology. 2022; 15(8):3475-8. doi: 10.52711/0974-360X.2022.00582 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-8-24
1. Burrell CJ, Howard CR, Murphy FA. Pathogenesis of virus infections. Fenner White’s Med Virol. 2017;77.
2. Nasir M, Wu GY. Review Article Prevention of HBV Recurrence after Liver Transplant: A Review. 2020;8:150–60, doi.org/10.14218%2FJCTH.2020.00003.
3. James D, Srinivas MR, Muthusekhar MR. Knowledge, Attitude and Practice on post exposure prophylaxis of Hepatitis among Dental undergraduates and Post-Graduates students at Saveetha Dental College and Hospital, Chennai–A Questionnaire Survey. Res J Pharm Technol. 2018;11(8):3320–2, doi.org/10.5958/0974-360X.2018.00610.8.
4. Sivakumar SM, Nirmala L, Swarnalakshmi R, Sivakumar L, Anilbabu B, Shanmugarajan TS, et al. Preparation and in vitro evaluation of Hepatitis B vaccine encapsulated chitosan microparticles. Res J Pharm Technol. 2009;2(1):117–9.
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 2006;131(6):1743–51, doi.org/10.1053/j.gastro.2006.09.020.
6. Kumar NK, Vigneswari D. Hepatitis-infectious disease prediction using classification algorithms. Res J Pharm Technol. 2019;12(8):3720–5, doi.org/10.5958/0974-360X.2019.00636.X.
7. Croagh CMN, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol. 2014; doi.org/10.3748%2Fwjg.v20.i30.10395
8. Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World Journal of Gastroenterology. 2009, doi.org/10.3748%2Fwjg.15.3099.
9. Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, et al. Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. J Gastroenterol Hepatol. 2020;1–8, doi.org/10.1111/jgh.15058.
10. Jawad M, Hashim K, Mahmood A. Prevalence of Anti-Viral Drug Resistance Chronic Hepatitis B patients (CHB) in Iraq. Res J Pharm Technol. 2018;11(8):3503–8, doi.org/10.5958/0974-360X.2018.00648.0.
11. Wang SH, Yeh SH, Chen PJ. Unique features of hepatitis b virus-related hepatocellular carcinoma in pathogenesis and clinical significance. Cancers (Basel). 2021;13(10):1–19, doi.org/10.4314/ahs.v20i2.13.
12. Fouad R, Musa S, Sabry D, Salama A, Alem SA, Atef M, et al. Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients. Afr Health Sci. 2020;20(2):649–55, doi.org/10.4314/ahs.v20i2.13.
13. Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine. 2021;67:103389,doi.org/10.1016/j.ebiom.2021.103389.
14. Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol WJG. 2014;20(24):7644, doi.org/10.3748%2Fwjg.v20.i24.7644.
15. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858, doi.org/10.1016/S0140-6736(18)32279-7.
16. Ayele A, Abera D, Hailu M, Birhanu M, Desta K. Prevalence and associated risk factors for Hepatitis B and C viruses among refugees in Gambella, Ethiopia. BMC Public Health. 2020;20:1–10, doi.org/10.1186/s12889-020-08893-1.
17. Assi WT, Moualla N, Ibrahim AI. Prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among hemodialysis (HD) patients in Aleppo city, Syria. Res J Pharm Technol. 2017;10(5):1301–4, doi.org/10.5958/0974-360X.2017.00230.X.
18. Cornberg M, Wong VWS, Locarnini S, Brunetto M, Janssen HLA, Chan HLY. The role of quantitative hepatitis B surface antigen revisited. Journal of Hepatology. 2017, doi.org/10.1016/j.jhep.2016.08.009.
19. Assi C, Ouattara A, Kone S, Soro D, Allah-Kouadio E, Kouakou CG, et al. Screening for Hepatitis B and C in Occupational Settings: Cross-Sectional Study about 4268 Corporates Agents in Côte d’Ivoire. Open J Gastroenterol. 2017;7(3):89–95, doi.org/10.4236/ojgas.2017.73010.
20. Hamdane H, Harfouch RM. Hepatitis B and C among blood donors in tartous city, syria. A retrospective study. Vol. 14, Research Journal of Pharmacy and Technology. 2021. p. 442–4, doi: 10.5958/0974-360X.2021.00080.9.
21. Pratha AA, Geetha R V. Awareness on Hepatitis-B vaccination among dental students-A Questionnaire Survey. Res J Pharm Technol. 2017;10(5):1360–2, doi.org/10.5958/0974-360X.2017.00240.2.
22. James G, Thomas A, Abraham TC, Prabu R, Panicker NK. HBV reactivation in patient receiving R-CVP regimen for the treatment of follicular lymphoma-A case report. Res J Pharm Technol. 2017;10(6):1645–6, doi: 10.5958/0974-360X.2017.00289.X
23. Chen Y, Chu C, Liaw Y. Age‐specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51(2):435–44, doi.org/10.1002/hep.23348.
24. The World Health Organisation. Guidelines on Hepatitis B and C Testing. Who. 2017, doi /www.who.int/about/licensing.
25. Jothivel N, Singaravel S, Deivasigamani K, Vasudevan M, Sundaram S, Sambasivam N, et al. Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’Patients for Their Carrier State. Res J Pharm Technol. 2008;1(3):259.
26. Kumar M, Kumar A, Hissar S, Jain P, Rastogi A, Kumar D, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int. 2008;28(5):690–8, doi.org/10.1111/j.1478-3231.2008.01711.x.
27. Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al‐Qahtani A, Al‐Ashgar HA, et al. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat. 2011;18(7):e217–25,doi.org/10.1111/j.1365-2893.2011.01437.x.
28. Al-Qahtani AA, Al-Anazi MR, Nazir N, Abdo AA, Sanai FM, Al-Hamoudi WK, et al. The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease. Front Cell Infect Microbiol. 2018;8(October):355, doi.org/10.3389/fcimb.2018.00355.
29. Teng CF, Wu HC, Su IJ, Jeng L Bin. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses. 2020;12(9), doi.org/10.3390/v12090945.
30. Saadi AA, Salih AM, Merza MA. Immunological and Biochemical Parameters of Chronic Hepatitis B Infection Among Patients in Duhok City–Kurdistan Region/Iraq. Duhok Med J. 2019;13(2):54–65, doi.org/10.31386/dmj.2019.12.1.6.
31. Al-Kanaan BMA, Al-Ouqaili MTS, Al-Rawi KFA. Comparative study of the molecular, biochemical, and other parameters in Iraqi hepatitis B patients. Drug Invent Today. 2020;14(6).